ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1774

Potential Involvement of OX40 Expressing Tfh Cells on Regulation of Autoantibody Sialylation in Experimental and Rheumatoid Arthritis

Izumi Kurata1, Isao Matsumoto 1, Natsuko Mikami 1, Ayako Ohyama 1, Atsumu Osada 1, Yuya Kondo 1, Hiroto Tsuboi 1 and Takayuki Sumida 1, 1Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Animal models, autoantibodies, pathogenesis and glycoproteins, rheumatoid arthritis, T cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: 4M093: RA – Animal Models (1770–1775)

Session Type: ACR Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Recently, IL-23-Th17 cells axis and hyposialylation of antibodies were proved to be linked to experimental and rheumatoid arthritis. However it remains uncertain how Tfh, including IL-17 producing Tfh (Tfh17) cells, behaves as regulator of antibody hyposialylation. The aim of this study is to explore the molecular mechanisms of Tfh17 cells-associated autoantibody hyposialylation using glucose-6-phosphate isomerase (GPI) induced arthritis (GIA) model and peripheral blood of RA patients.

Methods: 1) Fluctuation of Tfh cells and their cytokine production in draining lymph nodes were analyzed in GIA. Cell surface molecule expression of Tfh cells was examined.

2) Expression of st6gal1, the responsible enzyme for sialylation, in plasmablasts (PBs) was followed during arthritis course. Sialic acid in purified anti-GPI antibodies obtained at the arthritis onset (day 7) and resolving phase (day 28) was quantified by mass spectrometry. Dendritic cells (DCs) were stimulated with anti-GPI antibodies from both phases. Artificial sialic acid removal/supplement was performed in vitro and vivo.

3) Expression of st6gal1 in co-cultured PBs with Tfh cells was measured. OX40-OX40 ligand (OX40L) pathway was blocked with mAbs both in vivo and vitro.

4) Correlation between circulating Tfh17 cells, ACPA titers and st6gal1 expression in PBs were analyzed in treatment-naïve patients with RA. OX40 expression of Tfh17 cells was analyzed.

Results: 1) Tfh cells, especially IL-17 producing Tfh17 cells were increased at day 7 in GIA. They highly expressed OX40.

2) St6gal1 expression in PBs was significantly decreased at day 7 and 14 (arthritis peak) and gradually recovered. Mass spectrometric analysis revealed significant hyposialylation of day 7 antibodies. DCs produced more TNFα and CXCL1 when stimulated with day 7 antibodies than with those of day 28. Sialic acid-removed antibodies became stronger stimulants for DCs and GIA was ameliorated when sialic acid was supplied to mice.

3) Decreased expression of st6gal1 was observed in PBs co-cultured with Tfh cells. OX40-OX40L pathway blockade rescued this decrease in vitro. By the blockade, GIA was ameliorated accompanied by sialylated anti-GPI antibodies and diminished Tfh17 cells in vivo.

4) Proportion of circulating Tfh17 cells had positive correlation with ACPA tiers in RA patients. Moreover, they negatively correlated with the st6gal1 expression in RA patients (R2= -0.596). OX40 was highly expressed in their Tfh17 cells.

Conclusion: Our findings suggested Tfh, including Tfh17 cells could have a crucial role in the development of arthritis via regulation of autoantibody sialylation through OX40-OX40L axis in experimental and rheumatoid arthritis.


Disclosure: I. Kurata, None; I. Matsumoto, None; N. Mikami, None; A. Ohyama, None; A. Osada, None; Y. Kondo, None; H. Tsuboi, None; T. Sumida, None.

To cite this abstract in AMA style:

Kurata I, Matsumoto I, Mikami N, Ohyama A, Osada A, Kondo Y, Tsuboi H, Sumida T. Potential Involvement of OX40 Expressing Tfh Cells on Regulation of Autoantibody Sialylation in Experimental and Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/potential-involvement-of-ox40-expressing-tfh-cells-on-regulation-of-autoantibody-sialylation-in-experimental-and-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/potential-involvement-of-ox40-expressing-tfh-cells-on-regulation-of-autoantibody-sialylation-in-experimental-and-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology